(Press-News.org) MIAMI, FLORIDA (EMBARGOED UNTIL DEC. 8, 2025, AT 2:45 P.M. EST) – Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.
Lead researcher Juan Alderuccio, M.D., a hematologist and lymphoma specialist at Sylvester, will present this research Dec. 8 at the American Society of Hematology meeting in Orlando. The study’s findings could help standardize treatment for T-cell/histocyte-rich large B-cell lymphoma (THRLBCL) — a crucial step toward ensuring patients receive the most effective, least toxic care.
“Until this study, we didn't know exactly how to treat this disease,” Alderuccio said of THRLBCL. In the absence of a formal standard of care, physicians have been treating newly diagnosed patients with a variety of approaches. “Our aim was to identify the best first-line treatment considering patient and disease characteristics,” he said.
The study’s results indicate that most patients should receive a combination regimen known by the acronym R-CHOP, which is already established as an effective treatment for the most common type of large B cell lymphoma.
Previous research has suggested that patients with THRLBCL benefit from intensive chemotherapy regimens. However, this approach comes with a significant downside: frequent and considerable side effects. One study documented more infections, nerve pain, inflammation in the digestive tract and dangerously low levels of white blood cells in patients who received more intensive chemotherapy regimens than in those given R-CHOP.
To determine if R-CHOP could offer similar benefits without these drawbacks, the researchers compared results in THRLBCL to those of a cohort of patients with diffuse large B cell lymphoma (DLBCL), the most common large B cell lymphoma. THRLBCL tends to affect younger patients, especially men, who are often diagnosed at later stages in the cancer’s progression.
THRLBCL patients have fewer malignant B cells than their counterparts and more immune suppression, which benefits the cancer. This disease is also prone to spread to other organs, including the liver, lungs and bone marrow. It is also much less common. An analysis of patient data in the U.S. National Cancer Data Base counted 622 cases of THRLBCL from 2010 to 2015 and 91,588 cases of diffuse large B cell lymphoma for that period.
With so few patients, researchers have difficulty running the clinical trials typically used to establish standardized approaches to care, according to Alderuccio.
In the absence of this guidance, some oncologists turn to intensive chemotherapy, others use bone marrow transplantation, and still others administer R-CHOP. The latter regimen combines three chemotherapy drugs (cyclophosphamide, doxorubicin, vincristine), a steroid (prednisone) and the monoclonal antibody rituximab, which latches onto the CD20 protein on B cells. R-CHOP has proven highly effective in treating DLBCL. About 60% of these patients see their cancer disappear after completing the six cycles of R-CHOP.
For the study, Alderuccio and colleagues drew on three sources. They used data from THRLBCL patients collected by the Lymphoma Epidemiology of Outcomes consortium, which includes the University of Miami and seven other U.S. academic centers, and from the Czech Lymphoma Study Group in the Czech Republic. They compared these patients’ survival to that of their counterparts with DLBCL, data they obtained from these datasets, plus the Iowa University/Mayo Clinic Molecular Epidemiology Resource.
Of the 140 patients with THRLBCL, 106 received R-CHOP. Four years following treatment, 80% of these patients were still alive and 70% had not had their cancer return or experienced complications. The nearly 6,100 patients they included with diffuse large B cell lymphoma had similar outcomes. In fact, a statistical testing called propensity score matching showed no difference between the two, Alderuccio said. Meanwhile, intensive chemo regimens did not appear to improve the THRLBCL patients’ survival.
Next, he and his colleagues are expanding the study to include more patients from three new sources: the U.S. Department of Defense; the Veterans Administration registry; and a nationwide Danish cohort. Through this follow-up research, they hope to identify THRLBCL patients for whom R-CHOP is likely to fail, with the ultimate goal of conducting a clinical trial to assess alternatives for them.
about Sylvester research on the InventUM blog and follow @SylvesterCancer on X for the latest news on its research and care.
# # #
Presentation Title: Outcomes of T-cell/histocyte-rich large B-cell lymphoma (THRLBCL): An international LEO/MER and NiHiL collaborative study
Presentaton Date, Time and Location: Dec. 8, 2025, at 3:30PM EST; OCCC – Tangerine Ballroom F3-4
# # #
END
The sense of smell is vital for animals, as it helps them find food, protect themselves from predators and interact socially. An international research team led by Dr Quentin Martinez and Dr Eli Amson from State Museum of Natural History Stuttgart has now discovered that certain areas of the brain skull allow conclusions to be drawn about the sense of smell in mammals. Particularly significant is the volume of the endocast of the olfactory bulb, a bony structure in the skull that is often well preserved even in very old fossils. This volume is closely related to the number of intact odour receptor genes – an important ...
One of the most important steps in the evolution of modern mammals was the development of highly sensitive hearing. The middle ear of mammals, with an eardrum and several small bones, allows us to hear a broad range of frequencies and volumes, which was a big help to early, mostly nocturnal mammal ancestors as they tried to survive alongside dinosaurs.
New research by paleontologists from the University of Chicago shows that this modern mode of hearing evolved much earlier than previously thought. Working with detailed CT scans of the skull and jawbones of Thrinaxodon liorhinus, a 250-million-year-old mammal predecessor, they used engineering methods to simulate ...
The negative health impacts from contamination by so called "forever chemicals" in drinking water costs the contiguous U.S. at least $8 billion a year in social costs, a University of Arizona-led study has found.
The study, published in the Proceedings of the National Academy of Sciences, builds on previous research into how PFAS – per- and polyfluoroalkyl substances – can negatively impact health when the chemicals contaminate drinking water. The research team studied all births in New Hampshire from 2010-2019, focusing on mothers living ...
A new advance from Carnegie Mellon University researchers could reshape how clinicians identify the brain regions responsible for drug-resistant epilepsy. Surgery can be a life-changing option for millions of epilepsy patients worldwide, but only if physicians can accurately locate the epileptogenic zone, the area where seizures originate.
Bin He, professor of biomedical engineering, and his team have developed a unified, machine learning-based approach called spatial-temporal-spectral imaging (STSI) to assist. It is the first technology capable of analyzing every major type of epileptic ...
Irvine, Calif., Dec. 8, 2025 — With a $50 million lead gift from the Quilter family and approximately $30 million in new commitments, the University of California, Irvine’s Institute for Memory Impairments and Neurological Disorders will begin planning to build a state-of-the-art research and care facility to enhance its position as a global leader in Alzheimer’s disease and related dementias research and patient care.
UC Irvine alumni Charles Quilter, M.A. ’06, Ph.D. ’10, and Ann Quilter, M.S. ’79, and their family members Patrick, Chris, Matt and Patty made the generous contribution ...
URBANA, Ill. -- To meet ambitious U.S. Department of Energy targets for sustainable aviation fuel (SAF), production of purpose-grown energy crops must ramp up significantly. Although researchers have made substantial progress in understanding the management and conversion of these crops, key knowledge gaps hold the industry back. Now, two new studies from the University of Illinois Urbana-Champaign help fill in the blanks for Miscanthus and switchgrass management.
“We have come a long way in our understanding of purpose-grown energy crops for SAF, but we still ...
In the Middle Ages, a plague killed a third of Europe’s population. Fleas carried the plague bacterium, Yersinia pestis, transmitting the Black Death from infected rats to millions of people.
Another, earlier strain of Y. pestis emerged 5,000 years ago in the Bronze Age. It infected people throughout Eurasia for 2,000 years and then vanished. Unlike the Middle Age plague bacterium, this earlier Bronze Age strain could not be transmitted by fleas. How the plague circulated for so long across a vast area has long been a mystery.
Now, ...
December 8, 2025 — Millions of people already chat about their mental health with large language models (LLMs), the conversational form of artificial intelligence. Some providers have integrated LLM-based mental healthcare tools into routine workflows. John Torous, MD, MBI and colleagues, of the Division of Digital Psychiatry at Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, urge clinicians to take immediate action to ensure these tools are safe and helpful, not wait for ideal evaluation methodology to be developed. In the November issue ...
A good night’s sleep is more than a luxury: New research from Oregon Health & Science University suggests that insufficient sleep may shorten your life.
The study published today in the journal SLEEP Advances.
Researchers tapped a vast, nationwide database looking for survey trends associated with average life expectancy county by county. They compared county-level data about average life expectancy with comprehensive survey data collected by the Centers for Disease Control and Prevention between 2019 and 2025.
As a behavioral driver for life expectancy, sleep stood ...
WEST LAFAYETTE, Ind. — Intellicule, a software company whose solutions determine the 3D structures of biomolecules imaged with cryogenic-electron microscopy (cryo-EM), has received a $217,941 Small Business Innovation Research (SBIR) Phase I grant from the National Institutes of Health.
Daisuke Kihara, who leads Intellicule, said the grant will be used to develop software technology that could impact precision medicine.
“It will have the potential to accelerate the development of novel drugs by offering precise structural information that can guide the design of molecules with improved ...
